Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 1.733
Filtrar
1.
Respir Res ; 25(1): 293, 2024 Jul 31.
Artículo en Inglés | MEDLINE | ID: mdl-39085869

RESUMEN

BACKGROUND AND OBJECTIVE: Pooled analyses of previous randomized controlled trials reported that antifibrotics improved survival in patients with idiopathic pulmonary fibrosis (IPF), but the results were only based on short-term outcome data from selected patients who met strict criteria. Observational studies/meta-analyses also suggested that antifibrotics improve survival, but these studies failed to control for immortal time bias that considerably exaggerates drug effects. Therefore, whether antifibrotics truly improve long-term survival in patients with IPF in the real world remains undetermined and requires external validity. METHODS: We used data from the Japanese National Claims Database to estimate the intention-to-treat effect of antifibrotics on mortality. To address immortal time bias, we employed models treating antifibrotic initiation as a time-dependent covariate and target trial emulation (TTE), both incorporating new-user designs for antifibrotics and treating lung transplantation as a competing event. RESULTS: Of 30,154 patients with IPF, 14,525 received antifibrotics. Multivariate Fine-Gray models with antifibrotic initiation as a time-dependent covariate revealed that compared with no treatment, nintedanib (adjusted hazard ratio [aHR], 0.85; 95% confidence interval [CI], 0.81-0.89) and pirfenidone (aHR, 0.89; 95% CI, 0.86-0.93) were associated with reduced mortality. The TTE model also replicated the associations of nintedanib (aHR, 0.69; 95% CI, 0.65-0.74) and pirfenidone (aHR, 0.81; 95% CI, 0.78-0.85) with reduced mortality. Subgroup analyses confirmed this association regardless of age, sex, and comorbidities, excluding certain subpopulations. CONCLUSIONS: The results of this large-scale real-world analysis support the generalizability of the association between antifibrotics and improved survival in various IPF populations.


Asunto(s)
Antifibróticos , Fibrosis Pulmonar Idiopática , Humanos , Fibrosis Pulmonar Idiopática/tratamiento farmacológico , Fibrosis Pulmonar Idiopática/mortalidad , Fibrosis Pulmonar Idiopática/diagnóstico , Masculino , Femenino , Anciano , Persona de Mediana Edad , Antifibróticos/uso terapéutico , Factores de Tiempo , Japón/epidemiología , Sesgo , Piridonas/uso terapéutico , Reproducibilidad de los Resultados , Bases de Datos Factuales/tendencias , Tasa de Supervivencia/tendencias , Resultado del Tratamiento , Indoles
2.
BMC Neurol ; 24(1): 193, 2024 Jun 07.
Artículo en Inglés | MEDLINE | ID: mdl-38849716

RESUMEN

BACKGROUND: Dexmedetomidine (Dex), midazolam, and propofol are three distinct sedatives characterized by varying pharmacological properties. Previous literature has indicated the positive impact of each of these sedatives on ICU patients. However, there is a scarcity of clinical evidence comparing the efficacy of Dex, midazolam, and propofol in reducing mortality among people with epilepsy (PWE). This study aimed to assess the impact of Dex, midazolam, and propofol on the survival of PWE. METHODS: The data were retrospectively retrieved from the Medical Information Mart for Intensive Care (MIMIC)-IV database (version 2.0). PWE were categorized into Dex, midazolam, and propofol groups based on the intravenously administered sedatives. PWE without standard drug therapy were included in the control group. Comparative analyses were performed on the data among the groups. RESULTS: The Dex group exhibited a significantly lower proportion of in-hospital deaths and a markedly higher in-hospital survival time compared to the midazolam and propofol groups (p < 0.01) after propensity score matching. Kaplan-Meier curves demonstrated a significant improvement in survival rates for the Dex group compared to the control group (p = 0.025). Analysis of Variance (ANOVA) revealed no significant differences in survival rates among the Dex, midazolam, and propofol groups (F = 1.949, p = 0.143). The nomogram indicated that compared to midazolam and propofol groups, Dex was more effective in improving the survival rate of PWE. CONCLUSION: Dex might improve the survival rate of PWE in the ICU compared to no standard drug intervention. However, Dex did not exhibit superiority in improving survival rates compared to midazolam and propofol.


Asunto(s)
Dexmedetomidina , Epilepsia , Hipnóticos y Sedantes , Unidades de Cuidados Intensivos , Midazolam , Propofol , Humanos , Dexmedetomidina/uso terapéutico , Midazolam/uso terapéutico , Midazolam/administración & dosificación , Propofol/administración & dosificación , Propofol/uso terapéutico , Masculino , Femenino , Persona de Mediana Edad , Hipnóticos y Sedantes/uso terapéutico , Estudios Retrospectivos , Unidades de Cuidados Intensivos/estadística & datos numéricos , Epilepsia/tratamiento farmacológico , Epilepsia/mortalidad , Adulto , Anciano , Bases de Datos Factuales/tendencias , Mortalidad Hospitalaria/tendencias
3.
Respir Res ; 25(1): 216, 2024 May 23.
Artículo en Inglés | MEDLINE | ID: mdl-38783298

RESUMEN

The growing concern of pediatric mortality demands heightened preparedness in clinical settings, especially within intensive care units (ICUs). As respiratory-related admissions account for a substantial portion of pediatric illnesses, there is a pressing need to predict ICU mortality in these cases. This study based on data from 1188 patients, addresses this imperative using machine learning techniques and investigating different class balancing methods for pediatric ICU mortality prediction. This study employs the publicly accessible "Paediatric Intensive Care database" to train, validate, and test a machine learning model for predicting pediatric patient mortality. Features were ranked using three machine learning feature selection techniques, namely Random Forest, Extra Trees, and XGBoost, resulting in the selection of 16 critical features from a total of 105 features. Ten machine learning models and ensemble techniques are used to make accurate mortality predictions. To tackle the inherent class imbalance in the dataset, we applied a unique data partitioning technique to enhance the model's alignment with the data distribution. The CatBoost machine learning model achieved an area under the curve (AUC) of 72.22%, while the stacking ensemble model yielded an AUC of 60.59% for mortality prediction. The proposed subdivision technique, on the other hand, provides a significant improvement in performance metrics, with an AUC of 85.2% and an accuracy of 89.32%. These findings emphasize the potential of machine learning in enhancing pediatric mortality prediction and inform strategies for improved ICU readiness.


Asunto(s)
Mortalidad Hospitalaria , Unidades de Cuidado Intensivo Pediátrico , Aprendizaje Automático , Humanos , Niño , Mortalidad Hospitalaria/tendencias , Masculino , Femenino , Preescolar , Lactante , Unidades de Cuidado Intensivo Pediátrico/estadística & datos numéricos , Bases de Datos Factuales/tendencias , Adolescente , Recién Nacido , Valor Predictivo de las Pruebas , Enfermedades Respiratorias/mortalidad , Enfermedades Respiratorias/diagnóstico
4.
BMC Neurol ; 24(1): 178, 2024 May 27.
Artículo en Inglés | MEDLINE | ID: mdl-38802785

RESUMEN

BACKGROUND: Ischemic stroke (IS) and malignant tumor (MT) have high morbidity and mortality rates worldwide, and several associations exist between them. This study aimed to determine the effect of MT on hospital mortality in patients with IS. METHODS: Based on their MT status, participants with IS in the Medical Information Mart for Intensive Care IV (MIMIC-IV) were divided into two groups. The primary outcome was in-hospital all causes mortality. Kaplan-Meier survival analysis was performed to evaluate the intergroup in-hospital mortality, and three Cox regression models were used to determine the association between MT and in-hospital mortality. RESULTS: A total of 1605 participants (749 males and 856 females) were included in the study. The mean age was 72.030 ± 15.463 years. Of these, 257 (16%) patients died in the hospital. Kaplan-Meier analysis showed that the MT group had a significantly lower possibility of in-hospital survival than the non-MT group. In the unadjusted model, in-hospital mortality among MT patients had a higher odds ratio (OR) of 1.905 (95% CI, 1.320-2.748; P < 0.001) than the non-MT group. After adjusting for basic information, vital signs, and laboratory data, MT was also associated with increased in-hospital mortality (OR = 1.844, 95% CI: 1.255-2.708; P = 0.002). CONCLUSIONS: Among the patients with IS, the risk of all causes in-hospital mortality was higher for MT than for patients non-MT. This finding can assist clinicians in more accurately assessing prognosis and making informed treatment decisions.


Asunto(s)
Enfermedad Crítica , Mortalidad Hospitalaria , Accidente Cerebrovascular Isquémico , Humanos , Masculino , Femenino , Mortalidad Hospitalaria/tendencias , Anciano , Accidente Cerebrovascular Isquémico/mortalidad , Accidente Cerebrovascular Isquémico/diagnóstico , Enfermedad Crítica/mortalidad , Persona de Mediana Edad , Anciano de 80 o más Años , Neoplasias/mortalidad , Neoplasias/epidemiología , Bases de Datos Factuales/tendencias , Factores de Riesgo
5.
Int J Cardiol ; 407: 132105, 2024 Jul 15.
Artículo en Inglés | MEDLINE | ID: mdl-38677334

RESUMEN

BACKGROUND: Mitral valve disorder (MVD) stands as the most prevalent valvular heart disease. Presently, a comprehensive clinical index to predict mortality in MVD remains elusive. The aim of our study is to construct and assess a nomogram for predicting the 28-day mortality risk of MVD patients. METHODS: Patients diagnosed with MVD were identified via ICD-9 code from the MIMIC-III database. Independent risk factors were identified utilizing the LASSO method and multivariate logistic regression to construct a nomogram model aimed at predicting the 28-day mortality risk. The nomogram's performance was assessed through various metrics including the area under the curve (AUC), calibration curves, Hosmer-Lemeshow test, integrated discriminant improvement (IDI), net reclassification improvement (NRI), and decision curve analysis (DCA). RESULTS: The study encompassed a total of 2771 patients diagnosed with MVD. Logistic regression analysis identified several independent risk factors: age, anion gap, creatinine, glucose, blood urea nitrogen level (BUN), urine output, systolic blood pressure (SBP), respiratory rate, saturation of peripheral oxygen (SpO2), Glasgow Coma Scale score (GCS), and metastatic cancer. These factors were found to independently influence the 28-day mortality risk among patients with MVD. The calibration curve demonstrated adequate calibration of the nomogram. Furthermore, the nomogram exhibited favorable discrimination in both the training and validation cohorts. The calculations of IDI, NRI, and DCA analyses demonstrate that the nomogram model provides a greater net benefit compared to the Simplified Acute Physiology Score II (SAPSII), Acute Physiology Score III (APSIII), and Sequential Organ Failure Assessment (SOFA) scoring systems. CONCLUSION: This study successfully identified independent risk factors for 28-day mortality in patients with MVD. Additionally, a nomogram model was developed to predict mortality, offering potential assistance in enhancing the prognosis for MVD patients. It's helpful in persuading patients to receive early interventional catheterization treatment, for example, transcatheter mitral valve replacement (TMVR), transcatheter mitral valve implantation (TMVI).


Asunto(s)
Bases de Datos Factuales , Unidades de Cuidados Intensivos , Nomogramas , Humanos , Masculino , Femenino , Persona de Mediana Edad , Anciano , Bases de Datos Factuales/tendencias , Factores de Riesgo , Medición de Riesgo/métodos , Valor Predictivo de las Pruebas , Mortalidad/tendencias , Enfermedades de las Válvulas Cardíacas/mortalidad , Enfermedades de las Válvulas Cardíacas/diagnóstico , Estudios Retrospectivos , Válvula Mitral , Insuficiencia de la Válvula Mitral/mortalidad , Insuficiencia de la Válvula Mitral/diagnóstico
6.
Neuroinformatics ; 22(3): 229-238, 2024 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-38530566

RESUMEN

The increasing use of neuroimaging in clinical research has driven the creation of many large imaging datasets. However, these datasets often rely on inconsistent naming conventions in image file headers to describe acquisition, and time-consuming manual curation is necessary. Therefore, we sought to automate the process of classifying and organizing magnetic resonance imaging (MRI) data according to acquisition types common to the clinical routine, as well as automate the transformation of raw, unstructured images into Brain Imaging Data Structure (BIDS) datasets. To do this, we trained an XGBoost model to classify MRI acquisition types using relatively few acquisition parameters that are automatically stored by the MRI scanner in image file metadata, which are then mapped to the naming conventions prescribed by BIDS to transform the input images to the BIDS structure. The model recognizes MRI types with 99.475% accuracy, as well as a micro/macro-averaged precision of 0.9995/0.994, a micro/macro-averaged recall of 0.9995/0.989, and a micro/macro-averaged F1 of 0.9995/0.991. Our approach accurately and quickly classifies MRI types and transforms unstructured data into standardized structures with little-to-no user intervention, reducing the barrier of entry for clinical scientists and increasing the accessibility of existing neuroimaging data.


Asunto(s)
Imagen por Resonancia Magnética , Neuroimagen , Imagen por Resonancia Magnética/métodos , Humanos , Neuroimagen/métodos , Procesamiento de Imagen Asistido por Computador/métodos , Encéfalo/diagnóstico por imagen , Conjuntos de Datos como Asunto , Bases de Datos Factuales/tendencias
7.
Nucleic Acids Res ; 52(D1): D456-D465, 2024 Jan 05.
Artículo en Inglés | MEDLINE | ID: mdl-37994703

RESUMEN

The Electron Microscopy Data Bank (EMDB) is the global public archive of three-dimensional electron microscopy (3DEM) maps of biological specimens derived from transmission electron microscopy experiments. As of 2021, EMDB is managed by the Worldwide Protein Data Bank consortium (wwPDB; wwpdb.org) as a wwPDB Core Archive, and the EMDB team is a core member of the consortium. Today, EMDB houses over 30 000 entries with maps containing macromolecules, complexes, viruses, organelles and cells. Herein, we provide an overview of the rapidly growing EMDB archive, including its current holdings, recent updates, and future plans.


Asunto(s)
Bases de Datos Factuales , Microscopía Electrónica , Sustancias Macromoleculares , Microscopía Electrónica de Transmisión , Bases de Datos Factuales/normas , Bases de Datos Factuales/tendencias , Internet
8.
West Afr J Med ; 40(12): 1298-1303, 2023 Dec 30.
Artículo en Inglés | MEDLINE | ID: mdl-38261017

RESUMEN

BACKGROUND: Breast cancer outcomes are poor in Nigeria, partly due to late-stage diagnosis. To assess the impact of past and present interventions, a review of an institutional data base was performed to determine the trend with respect to stage at diagnosis over a decade. METHODS: A retrospective analysis of an institutional data base was performed over a decade. The review period was divided into segments (2013-2015, 2016-2018 and 2019-2022). The latter period (2019-2022), corresponds to a time of more intense community interventions aimed at promoting early diagnosis and treatment around the locality of the teaching hospital. The stage at diagnosis within these periods were compared. The relationship between stage and sociodemographic variables (age, religion, marital status, menopausal status, and level of education) was assessed. RESULTS: There were 910 patients, 144 within the first period (2013-2015), 318 in the second (2016-2018) and 454 in the third period (2019-2022). The majority presented with stage 3 disease (73.8%). There was a significant decline in the proportion of metastatic cases and a concomitant increase in early cases in the latter part of the review. The proportion of metastatic cases reduced from 23.6% (2013-2015), to 15.7% (2016-2018) and 9.3% (2019-2022) (p=0.001). Level of education was significantly associated with stage (p=0.001). CONCLUSION: This study shows a trend towards downstaging of breast cancer in our locality. This trend corresponds to the period of more intense community interventions, justifying the need to further interrogate the direct impact of each of the interventions. This will provide a firm basis for sustaining or improving on current efforts to achieve more robust gains.


CONTEXTE: Les résultats du cancer du sein sont médiocres au Nigeria, en partie en raison d'un diagnostic tardif. Pour évaluer l'impact des interventions passées et actuelles, une revue d'une base de données institutionnelle a été réalisée pour déterminer la tendance en ce qui concerne le stade au moment du diagnostic sur une décennie. MÉTHODES: Une analyse rétrospective d'une base de données institutionnelle a été effectuée sur une décennie. La période de revue a été divisée en segments (2013-2015, 2016-2018 et 2019-2022). La dernière période (2019-2022) correspond à une période d'interventions communautaires plus intensives visant à promouvoir un diagnostic précoce et un traitement autour de la localité de l'hôpital universitaire. Les stades au moment du diagnostic au cours de ces périodes ont été comparés. La relation entre le stade et les variables sociodémographiques (âge, religion, état matrimonial, statut ménopausique et niveau d'éducation) a été évaluée. RÉSULTATS: Il y avait 910 patients, 144 dans la première période (2013-2015), 318 dans la deuxième (2016-2018) et 454 dans la troisième période (2019-2022). La majorité présentait une maladie de stade 3 (73,8 %). On a observé une diminution significative de la proportion de cas métastatiques et une augmentation concomitante des cas précoces dans la dernière partie de la revue. La proportion de cas métastatiques est passée de 23,6 % (2013-2015) à 15,7 % (2016- 2018) et 9,3 % (2019-2022) (p=0,001). Le niveau d'éducation était significativement associé au stade (p=0,001). CONCLUSION: Cette étude montre une tendance à la réduction du stade du cancer du sein dans notre localité. Cette tendance correspond à la période d'interventions communautaires plus intenses, justifiant la nécessité d'interroger davantage l'impact direct de chacune des interventions. Cela fournira une base solide pour soutenir ou améliorer les efforts actuels afin d'obtenir des gains plus robustes. Mots-clés: Sein, Cancer, Stade, Nigéria.


Asunto(s)
Neoplasias de la Mama , Detección Precoz del Cáncer , Promoción de la Salud , Hospitales de Enseñanza , Femenino , Humanos , Población Negra/estadística & datos numéricos , Neoplasias de la Mama/diagnóstico , Neoplasias de la Mama/patología , Hospitales de Enseñanza/estadística & datos numéricos , Estudios Retrospectivos , Detección Precoz del Cáncer/estadística & datos numéricos , Detección Precoz del Cáncer/tendencias , Bases de Datos Factuales/estadística & datos numéricos , Bases de Datos Factuales/tendencias , Nigeria/epidemiología , Promoción de la Salud/estadística & datos numéricos , Promoción de la Salud/tendencias , Escolaridad , Relaciones Comunidad-Institución/tendencias
9.
PLoS Med ; 19(2): e1003896, 2022 02.
Artículo en Inglés | MEDLINE | ID: mdl-35134080

RESUMEN

BACKGROUND: Use of patient-reported outcomes (PROs) and patient and public engagement are critical ingredients of pragmatic trials, which are intended to be patient centered. Engagement of patients and members of the public in selecting the primary trial outcome and determining the target difference can better ensure that the trial is designed to inform the decisions of those who ultimately stand to benefit. However, to the best of our knowledge, the use and reporting of PROs and patient and public engagement in pragmatic trials have not been described. The objectives of this study were to review a sample of pragmatic trials to describe (1) the prevalence of reporting patient and public engagement; (2) the prevalence and types of PROs used; (3) how its use varies across trial characteristics; and (4) how sample sizes and target differences are determined for trials with primary PROs. METHODS AND FINDINGS: This was a methodological review of primary reports of pragmatic trials. We used a published electronic search filter in MEDLINE to identify pragmatic trials, published in English between January 1, 2014 and April 3, 2019; we identified the subset that were registered in ClinicalTrials.gov and explicitly labeled as pragmatic. Trial descriptors were downloaded from ClinicalTrials.gov; information about PROs and sample size calculations were extracted from the manuscript. Chi-squared, Cochran-Armitage, and Wilcoxon rank sum tests were used to examine associations between trial characteristics and use of PROs. Among 4,337 identified primary trial reports, 1,988 were registered in CT.gov, of which 415 were explicitly labeled as pragmatic. Use of patient and public engagement was identified in 39 (9.4%). PROs were measured in 235 (56.6%): 144 (34.7%) used PROs as primary outcomes and 91 (21.9%) as only secondary outcomes. Primary PROs were symptoms (64; 44%), health behaviors (36; 25.0%), quality of life (17; 11.8%), functional status (16; 11.1%), and patient experience (10; 6.9%). Trial characteristics with lower prevalence of use of PROs included being conducted exclusively in children or adults over age 65 years, cluster randomization, recruitment in low- and middle-income countries, and primary purpose of prevention; trials conducted in Europe had the highest prevalence of PROs. For the 144 trials with a primary PRO, 117 (81.3%) reported a sample size calculation for that outcome; of these, 71 (60.7%) justified the choice of target difference, most commonly, using estimates from pilot studies (31; 26.5%), standardized effect sizes (20; 17.1%), or evidence reviews (16; 13.7%); patient or stakeholder opinions were used to justify the target difference in 8 (6.8%). Limitations of this study are the need for trials to be registered in ClinicalTrials.gov, which may have reduced generalizability, and extracting information only from the primary trial report. CONCLUSIONS: In this study, we observed that pragmatic trials rarely report patient and public engagement and do not commonly use PROs as primary outcomes. When provided, target differences are often not justified and rarely informed by patients and stakeholders. Research funders, scientific journals, and institutions should support trialists to incorporate patient engagement to fulfill the mandate of pragmatic trials to be patient centered.


Asunto(s)
Participación del Paciente/métodos , Medición de Resultados Informados por el Paciente , Ensayos Clínicos Pragmáticos como Asunto/métodos , Ensayos Clínicos Controlados Aleatorios como Asunto/métodos , Estudios Transversales , Bases de Datos Factuales/tendencias , Humanos , Participación del Paciente/tendencias
10.
Oxid Med Cell Longev ; 2022: 8661864, 2022.
Artículo en Inglés | MEDLINE | ID: mdl-35087622

RESUMEN

Ferroptosis, an iron-dependent form of regulated cell death, has drawn an increasing amount of attention since it was first mentioned in 2012 and is found to play a significant role in the treatment of certain diseases. Our study is aimed at analysing the scientific output of ferroptosis research and at driving future research into novel publications. Publications focused on ferroptosis were retrieved from the SCI-EXPANDED database of the Web of Science Core Collection and were screened according to inclusion criteria. CiteSpace V and Microsoft Excel 2016 were used to evaluate and visualize the results, including generating network maps and analysing annual publications, country, category, references and cocited references, and keywords. As of October 1, 2021, a total of 1690 original articles related to ferroptosis were included, and the overall trend of the number of publications rapidly increased. Among the common categories in the field of ferroptosis, the most common category was biochemistry and molecular biology. Worldwide, China and the United States were the leading countries for research production. The retrieved 1690 publications received 44,650 citations, with an average of 26.42 citations per paper (October 1, 2021). By citation analysis, Scott J Dixon's article in 2012 was the most symbolic reference and the earliest publication in the field of ferroptosis, with the highest citation rate (2709 times). Among the most common keywords, most were related to the mechanisms and regulatory networks of ferroptosis. Furthermore, with accumulating evidence demonstrating the role of ferroptosis in cancers and other diseases, inducing ferroptosis in clinical treatment is becoming a new research focus that should be closely monitored.


Asunto(s)
Bibliometría , Investigación Biomédica/tendencias , Bases de Datos Factuales/tendencias , Ferroptosis/fisiología , Humanos
11.
Anesth Analg ; 134(2): 357-368, 2022 02 01.
Artículo en Inglés | MEDLINE | ID: mdl-33999011

RESUMEN

BACKGROUND: The association between race and perioperative outcomes has been evaluated in adult cardiac surgical and in healthy pediatric patients but has not been evaluated in children with congenital heart disease (CHD) presenting for noncardiac procedures. This study compares the incidence of the primary outcome of 30-day mortality and adverse postoperative outcomes following noncardiac surgery between Black and White children with CHD, stratified by severity. METHODS: This is a retrospective study. Comparison of outcomes between Black and White children was performed using the 2012-2018 American College of Surgeons National Surgical Quality Improvement Program Pediatric database and after stratification for severity of CHD and propensity score matching. RESULTS: A total of 55,859 patients were included, and divided into 28,601 minor, 23,839 major, and 3419 severe CHD. Black and White children in each category were matched and compared. Following matching in the overall CHD cohort, there were significantly higher rates of the following adverse postoperative outcomes among Black patients as compared to White patients: 30-day mortality (1.84% vs 1.49%; odds ratio [OR], 1.25; 95% confidence interval [CI], 1.05-1.48; P = .014), composite secondary outcomes (19.90% vs 17.88%; OR, 1.14; 95% CI, 1.08-1.21; P < .001), cardiac arrest (1.42% vs 0.98%; OR, 1.46; 95% CI, 1.19-1.79; P < .001), 30-day reoperation (7.59% vs 6.67%; OR, 1.15; 95% CI, 1.05-1.25; P = .002), and reintubation (3.9% vs 2.95%; OR, 1.34; 95% CI, 1.19-1.52; P < .001). No significant statistical interaction between race and CHD severity was found. Following matching and within the minor CHD cohort, Black children had significantly higher rates of composite secondary outcome (17.44% vs 15.60%; OR, 1.15; 95% CI, 1.05-1.25; P = .002), cardiac arrest (1.02% vs 0.53%; OR, 1.94; 95% CI, 1.37-2.76; P < .001), 30-day reoperation (7.19% vs 5.77%; OR, 1.26; 95% CI, 1.11-1.43; P < .001), and thromboembolic complications (0.49% vs 0.23%; OR, 2.17; 95% CI, 1.29-3.63; P = .003) compared to White children. In the major CHD cohort, Black children had significantly higher rates of 30-day mortality (2.75% vs 2.05%; OR, 1.35; 95% CI, 1.08-1.69; P = .008) and reintubation (4.82% vs 3.72%; OR, 1.32; 95% CI, 1.11-1.56; P = .002). There were no statistically significant differences in outcomes in the severe CHD category for 30-day mortality (3.36% vs 3.3%; OR, 1.02; 95% CI, 0.60-1.73; P = .946), composite secondary outcome (22.65% vs 21.36%; OR, 1.08; 95% CI, 0.86-1.36; P = .517) nor the components of the composite secondary outcomes. CONCLUSIONS: Race is associated with postoperative mortality and complications in children with minor and major CHD undergoing noncardiac surgery. No significant association was observed between race and postoperative outcomes in patients with severe CHD. This is consistent with previous findings wherein in patients with severe CHD, residual lesion burden and functional status is the leading predictor of outcomes following noncardiac surgery. Nevertheless, there is no evidence that the relationship between race and outcomes differs across the CHD severity categories. Future studies to understand the mechanisms leading to the racial difference, including institutional, clinical, and individual factors are needed.


Asunto(s)
Cardiopatías Congénitas/epidemiología , Cardiopatías Congénitas/cirugía , Complicaciones Posoperatorias/epidemiología , Grupos Raciales , Adolescente , Niño , Preescolar , Bases de Datos Factuales/tendencias , Femenino , Cardiopatías Congénitas/diagnóstico , Humanos , Lactante , Masculino , Complicaciones Posoperatorias/diagnóstico , Estudios Retrospectivos , Resultado del Tratamiento
12.
World Neurosurg ; 157: e333-e341, 2022 01.
Artículo en Inglés | MEDLINE | ID: mdl-34653703

RESUMEN

OBJECTIVE: The optimal management of intraventricular metastases remains debatable. The aim of this study is to define the safety and efficacy of Gamma-Knife radiosurgery in the treatment of intraventricular metastases. METHODS: This retrospective, single-center study involved patients that were treated with stereotactic radiosurgery (SRS) for intraventricular metastases. The study end points included SRS-related toxicity, local and distal intracranial tumor control, as well as the incidence of post-treatment hydrocephalus and leptomeningeal dissemination. Factors associated with radiologic and clinical outcomes were also analyzed. RESULTS: The cohort included 17 consecutive patients who underwent stereotactic radiosurgery for treatment of 41 intracranial metastases, of which 23 were primary intraventricular (intraventricular metastasis). Median overall survival from primary tumor diagnosis and from SRS treatment were 28 and 5 months, respectively. With a median radiological follow-up of 3 (interquartile range 3) months, 7 patients (41.18%) experienced overall intracranial disease progression, whereas 7 (27.27%) intraventricular metastases progressed radiologically. Four (23.53%) and 3 (17.65%) patients developed hydrocephalus and leptomeningeal dissemination post-SRS, respectively. Four patients (23.53%) died due to intracranial disease progression. CONCLUSIONS: SRS offers a reasonable chance of local tumor control for patients with intraventricular brain metastasis. However, the risk of hydrocephalus and leptomeningeal spread of disease is not inconsequential and merits close follow-up for patients with brain metastasis involving the ventricular system.


Asunto(s)
Neoplasias del Ventrículo Cerebral/mortalidad , Neoplasias del Ventrículo Cerebral/cirugía , Radiocirugia/mortalidad , Radiocirugia/tendencias , Anciano , Neoplasias del Ventrículo Cerebral/diagnóstico por imagen , Estudios de Cohortes , Bases de Datos Factuales/tendencias , Femenino , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Estudios Retrospectivos , Tasa de Supervivencia/tendencias , Resultado del Tratamiento
13.
World Neurosurg ; 157: e271-e275, 2022 01.
Artículo en Inglés | MEDLINE | ID: mdl-34637938

RESUMEN

INTRODUCTION: High-speed motor vehicle accidents (MVAs) are an important cause of brachial plexus injury (BPI). Some case reports have demonstrated shoulder seat belt use resulting in traction injuries to the brachial plexus. We used a national trauma registry to determine the association between seat belt use and brachial plexus injury in MVAs. METHODS: The authors queried the National Trauma Databank between 2016 and 2017 for patients with a hospital admission following an MVA. Cases with BPI were identified using International Classification of Diseases, Tenth Edition, Clinical Modification, diagnosis codes. Case-control matching by age and sex was performed to identify 2 non-BPI controls for every case of BPI. Multivariable conditional logistic regression adjusting for body mass index, alcohol use, and drug use was then performed to determine the adjusted association between safety equipment use (seat belt use and airbag deployment) and BPI. RESULTS: A total of 526,007 cases of MVAs were identified, of which 704 (0.13%) sustained a BPI. The incidences of BPI in patients were the following without any protective device (0.16%), with airbag deployment alone (0.08%), with seat belt use alone (0.08%), and with combined airbag deployment and seat belt use (0.07%). Following 1:2 case-control matching by age and sex and multivariable conditional logistic regression, seat belt use (odds ratio [OR] 0.55; 95% confidence interval [CI] 0.42-0.71; P < 0.001) and airbag deployment (OR 0.52; 95% CI 0.33-0.82; P = 0.004) were found to be associated with decreased odds for BPI, with the least odds observed with combined seat belt use and airbag deployment (OR 0.49; 95% CI 0.33-0.74; P = 0.001). CONCLUSIONS: Despite anecdotal evidence suggesting increased likelihood of BPI with shoulder seat belt use, case-control analysis from a national trauma registry demonstrated that both seat belt use and airbag deployment are associated with lower odds of sustaining BPIs in MVAs, with the greatest protective effect observed with combined use. Future studies adjusting for rider location (passenger vs. driver) and other potential confounders such as make, type and speed of vehicle may help further characterize this association.


Asunto(s)
Accidentes de Tránsito/tendencias , Airbags/tendencias , Plexo Braquial/lesiones , Bases de Datos Factuales/tendencias , Cinturones de Seguridad/tendencias , Accidentes de Tránsito/prevención & control , Adulto , Airbags/normas , Estudios de Casos y Controles , Femenino , Humanos , Masculino , Persona de Mediana Edad , Cinturones de Seguridad/normas , Estados Unidos/epidemiología , Adulto Joven
14.
Stroke ; 53(1): 128-133, 2022 01.
Artículo en Inglés | MEDLINE | ID: mdl-34610754

RESUMEN

BACKGROUND AND PURPOSE: Despite the lower rates of good outcomes and higher mortality in elderly patients, age does not modify the treatment effect of mechanical thrombectomy for large vessel occlusion strokes. We aimed to study whether racial background influences the outcome after mechanical thrombectomy in the elderly population. METHODS: We reviewed a prospectively maintained database of patients with acute ischemic stroke treated with mechanical thrombectomy from October 2010 through June 2020 to identify all consecutive patients with age ≥80 years and anterior circulation large vessel occlusion strokes. The patients were categorized according to their race as Black and White. Univariable and multivariable analyses were performed to define the predictors of 90-day modified Rankin Scale and mortality in the overall population and in each race separately. RESULTS: Among 2241 mechanical thrombectomy, a total of 344 patients (median [interquartile range]; age 85 [82-88] years, baseline National Institutes of Health Stroke Scale score of 19 [15-23], Alberta Stroke Program Early CT Score 9 [7-9], 69.5% females) were eligible for the analysis. White patients (n=251; 73%) had significantly lower median body mass index (25.37 versus 26.89, P=0.04) and less frequent hypertension (78.9% versus 90.3%, P=0.01) but more atrial fibrillation (64.5% versus 44.1%, P=0.001) compared with African Americans (n=93; 27%). Other clinical, imaging, and procedural characteristics were comparable between groups. The rates of symptomatic intracerebral hemorrhage, 90-day modified Rankin Scale score of 0 to 2, and mortality were comparable among both groups. On multivariable analysis, race was neither a predictor of 90-day modified Rankin Scale score of 0 to 2 (White race: odds ratio, 0.899 [95% CI, 0.409-1.974], P=0.79) nor 90-day mortality (White race: odds ratio, 1.368; [95% CI, 0.715-2.618], P=0.34). CONCLUSIONS: In elderly patients undergoing mechanical thrombectomy for acute ischemic stroke, there was no racial difference in terms of outcome.


Asunto(s)
Isquemia Encefálica/etnología , Procedimientos Endovasculares/tendencias , Disparidades en Atención de Salud/etnología , Disparidades en Atención de Salud/tendencias , Evaluación de Resultado en la Atención de Salud/tendencias , Accidente Cerebrovascular/etnología , Negro o Afroamericano/etnología , Anciano de 80 o más Años , Isquemia Encefálica/terapia , Bases de Datos Factuales/tendencias , Femenino , Humanos , Masculino , Estudios Prospectivos , Racismo/etnología , Racismo/tendencias , Estudios Retrospectivos , Determinantes Sociales de la Salud/etnología , Determinantes Sociales de la Salud/tendencias , Accidente Cerebrovascular/terapia , Población Blanca/etnología
15.
Stroke ; 53(1): 53-60, 2022 01.
Artículo en Inglés | MEDLINE | ID: mdl-34517764

RESUMEN

BACKGROUND AND PURPOSE: The occurrence of pneumonia after stroke is associated with a higher risk of poor outcome or death. We assessed the temporal profile of pneumonia after stroke and its association with poor outcome at several time points to identify the most optimal period for testing pneumonia prevention strategies. METHODS: We analyzed individual patient data stored in the VISTA (Virtual International Stroke Trials Archive) from randomized acute stroke trials with an inclusion window up to 24 hours after stroke onset and assessed the occurrence of pneumonia in the first 90 days after stroke. Adjusted odds ratios and hazard ratios were calculated for the association between pneumonia and poor outcome and death by means of logistic and Cox proportional hazard regression, respectively, at different times of follow-up. RESULTS: Of 10 821 patients, 1017 (9.4%) had a total of 1076 pneumonias. Six hundred eighty-nine (64.0%) pneumonias occurred in the first week after stroke. The peak incidence was on the third day and the median time of onset was 4.0 days after stroke (interquartile range, 2-12). The presence of a pneumonia was associated with an increased risk of poor outcome (adjusted odds ratio, 4.8 [95% CI, 3.8-6.1]) or death (adjusted hazard ratio, 4.1 [95% CI, 3.7-4.6]). These associations were present throughout the 90 days of follow-up. CONCLUSIONS: Two out of 3 pneumonias in the first 3 months after stroke occur in the first week, with a peak incidence on the third day. The most optimal period to assess pneumonia prevention strategies is the first 4 days after stroke. However, pneumonia occurring later was also associated with poor functional outcome or death.


Asunto(s)
Isquemia Encefálica/diagnóstico por imagen , Isquemia Encefálica/epidemiología , Neumonía/diagnóstico , Neumonía/epidemiología , Accidente Cerebrovascular/diagnóstico por imagen , Accidente Cerebrovascular/epidemiología , Anciano , Anciano de 80 o más Años , Bases de Datos Factuales/tendencias , Femenino , Humanos , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Estudios Retrospectivos , Factores de Tiempo
16.
Front Endocrinol (Lausanne) ; 12: 797049, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-34970227

RESUMEN

Background: The harmful effect of diabetes mellitus (DM) on mortality in patients with acute myocardial infarction (AMI) remains controversial. Furthermore, few studies focused on critical AMI patients. We aimed to address whether DM increases short- and long-term mortality in this specific population. Methods: We analyzed AMI patients admitted into coronary care unit (CCU) with follow-up of ≥1 year from two cohorts (MIMIC-III, Medical Information Mart for Intensive Care III; CIN, Cardiorenal ImprovemeNt Registry) in the United States and China. Main outcome was mortality at 30-day and 1-year following hospitalization. Kaplan-Meier curves and Cox proportional hazards models were constructed to examine the impact of DM on mortality in critical AMI patients. Results: 1774 critical AMI patients (mean age 69.3 ± 14.3 years, 46.1% had DM) were included from MIMIC-III and 3380 from the CIN cohort (mean age 62.2 ± 12.2 years, 29.3% had DM). In both cohorts, DM group was older and more prevalent in cardio-renal dysfunction than non-DM group. Controlling for confounders, DM group has a significantly higher 30-day mortality (adjusted odds ratio (aOR) (95% CI): 2.71 (1.99-3.73) in MIMIC-III; aOR (95% CI): 9.89 (5.81-17.87) in CIN), and increased 1-year mortality (adjusted hazard ratio (aHR) (95% CI): 1.91 (1.56-2.35) in MIMIC-III; aHR (95% CI): 2.62(1.99-3.45) in CIN) than non-DM group. Conclusions: Taking into account cardio-renal function, critical AMI patients with DM have a higher 30-day mortality and 1-year mortality than non-DM group in both cohorts. Further studies on prevention and management strategies for DM are needed for this population. Clinical Trial Registration: clinicaltrials.gov, NCT04407936.


Asunto(s)
Enfermedad Crítica/mortalidad , Diabetes Mellitus Tipo 2/diagnóstico , Diabetes Mellitus Tipo 2/mortalidad , Infarto del Miocardio/diagnóstico , Infarto del Miocardio/mortalidad , Anciano , Anciano de 80 o más Años , China/epidemiología , Estudios de Cohortes , Bases de Datos Factuales/tendencias , Femenino , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , Mortalidad/tendencias , Sistema de Registros , Estudios Retrospectivos , Factores de Riesgo , Factores de Tiempo , Estados Unidos/epidemiología
17.
Probl Radiac Med Radiobiol ; 26: 199-218, 2021 Dec.
Artículo en Inglés, Ucraniano | MEDLINE | ID: mdl-34965549

RESUMEN

Objective of research is to improve the electronic database of WBC measurements dated 1986 by inputting of newinformation from paper carriers, reconstruction of information gaps, verification and analysis of new entered data,revision of internal exposure doses that are based on results of WBC measurements dated 1986. MATERIALS AND METHODS: In 2013-2015 during a revision of databases (DB) of WBC measurements results dated1986-2014, it was discovered a great amount of paper carriers with information about WBC measurements, includ-ing the ones dated 1986, that were not inputted to the electronic DB. The paper carriers were systematized andordered by the following indicators: place of residence of a person and place of WBC measurement, institution andoperator that made the measurement, measurement device and date of measurement. For a comfortable inputtingof the information to the electronic DB, it was additionally created a form which exists as an option in existing program complex Silbody (Version 19.0.9). In the revised DB of WBC measurements dated 1986 internal exposure dosesfrom radio-cesium of Chornobyl origin were computed based on an ecological and dosimetric model for radio-cesiummigration in environment and a model for radio-cesium metabolism in human body. In the work, mathematical andstatistical methods of research were used. RESULTS: In 2019-2021 additionally 35,319 notes were inputted to the electronic DB of WBC measurement dated1986, and as a result its volume increased in 2.2 times. Mostly those are data on results concerning residents of Kyiv,Zhytomyr, Donetsk, Cherkasy, Odessa, Ivano-Frankivsk, and Rivne Oblasts. It was established the information onmeasurement devices and respectively on the minimal detected activity (MDA) for 27,119 notes (76.7 % of all newentered). Information is reconstructed about the body mass of all persons under investigation. Evaluation is madefor values of intake of incorporated radionuclides 137Cs and 134Cs for all new entered to DB. Quality of reconstructedinformation was analyzed. To group 1, «qualitative¼, it was classified 18,598 notes (53 % of all new entered), measurements in 1986 (including new entered). Dose not exceeding 1 mSv was obtained by 80 % of adults (older than20), as well as 73 % of persons younger than 20. CONCLUSION: To DB of WBC measurements, it was additionally inputted 35,319 notes on results of measurementsdated 1986. New entered information is verified and distributed by the quality groups. Individual exposure dosesevaluated based on those data can be used for further scientific research.


Asunto(s)
Accidente Nuclear de Chernóbil , Bases de Datos Factuales/estadística & datos numéricos , Bases de Datos Factuales/tendencias , Exposición a la Radiación/estadística & datos numéricos , Monitoreo de Radiación/estadística & datos numéricos , Radiometría/estadística & datos numéricos , Recuento Corporal Total/estadística & datos numéricos , Exactitud de los Datos , Recolección de Datos/estadística & datos numéricos , Recolección de Datos/tendencias , Monitoreo Epidemiológico , Predicción , Humanos , Sistema de Registros , Ucrania
18.
Diabetes Metab Syndr ; 15(6): 102331, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-34781137

RESUMEN

BACKGROUND AND AIMS: In recent decades, modeling and forecasting have played a significant role in the diagnosis and treatment of different diseases. Various forecasting models have been developed to improve data-based decision-making processes in medical systems. Although these models differ in many aspects, they all originate from the assumption that more generalizable results are achieved by more accurate models. This means that accuracy is considered as the only prominent feature to evaluate the generalizability of forecasting models. On the other side, due to the changeable medical situations and even changeable models' results, making stable and reliable performance is necessary to adopt appropriate medical decisions. Hence, reliability and stability of models' performance is another effective factor on the model's generalizability that should be taken into consideration in developing medical forecasting models. METHODS: In this paper, a new reliability-based forecasting approach is developed to address this gap and achieve more consistent performance in making medical predictions. The proposed approach is implemented on the classic regression model which is a common accuracy-based statistical method in medical fields. To evaluate the effectiveness of the proposed model, it has been performed by using two medical benchmark datasets from UCI and obtained results are compared with the classic regression model. RESULTS: Empirical results show that the proposed model has outperformed the classic regression model in terms of error criteria such as MSE and MAE. So, the presented model can be utilized as an appropriate alternative for the traditional regression model in making effective medical decisions. CONCLUSIONS: Based on the obtained results, the proposed model can be an appropriate alternative for traditional multiple linear regression for modeling in real-world applications, especially when more generalization and/or more reliability is needed.


Asunto(s)
Toma de Decisiones Clínicas/métodos , Bases de Datos Factuales/tendencias , Investigación Empírica , Bases de Datos Factuales/estadística & datos numéricos , Predicción/métodos , Humanos , Análisis de Regresión , Reproducibilidad de los Resultados
20.
Clin Neurol Neurosurg ; 210: 107007, 2021 11.
Artículo en Inglés | MEDLINE | ID: mdl-34741974

RESUMEN

OBJECTIVE: The importance of environmental factors (especially leptospirosis) of moyamoya disease (MMD) has not been clarified. Here we investigated the epidemiological characteristics of MMD in Hubei province, China. METHODS: We conducted a population-based study to describe the epidemiologic characteristics of MMD in Hubei province between 2017 and 2019. The regional clusters of the hot spots (high incidence) and cold spots (low incidence) of MMD were identified using the spatial statistical method. To evaluate the role of leptospirosis in MMD, we performed an ecological comparison study to evaluate whether the socioeconomic and environmental variables of hot spots are more suitable for leptospirosis spread. RESULTS: The average annual sex and age adjusted incidence of MMD was 3.07 per 100,000 person-years from 2017 to 2019. The middle-aged had apparently higher incidence of MMD than the children. There existed an obvious geographic distribution difference of MMD at county level. The hot spots were identified mainly in the low mountainous and hilly terrain, while cold spots were located in the Jianghan Plains. Compared to cold spots, the hot spots had larger cattle density (32.0 vs 3.1, p = 0.002), higher percentages of rice field (85.6% vs 47.0%, p = 0.007), and lower elevation (33.6 vs 157.4, p < 0.001) CONCLUSIONS: There exists geographic distribution difference of MMD in Hubei province and was likely to be caused by leptospirosis in the early years. The MMD in China is dominant by middle-aged adults, which might be driven from leptospirosis outbreaks in the last century.


Asunto(s)
Ecosistema , Leptospirosis/diagnóstico , Leptospirosis/epidemiología , Enfermedad de Moyamoya/diagnóstico , Enfermedad de Moyamoya/epidemiología , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Animales , Bovinos , Niño , Preescolar , China/epidemiología , Bases de Datos Factuales/tendencias , Femenino , Humanos , Lactante , Masculino , Persona de Mediana Edad , Sistema de Registros , Factores de Riesgo , Porcinos , Adulto Joven
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA